RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Immune Mediated Necrotizing Myopathy (IMNM). According to GlobalData, Phase I drugs for Immune Mediated ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Unfortunately, clinical evaluation and diagnostic tests sometimes fail to determine whether a necrotizing myopathy is immune mediated, resulting in undertreatment of autoimmune myopathies or ...

Autoimmune myositis (AIM) is a group of diseases affecting skin and muscles in both children and adults. The spectrum of AIM includes polymyositis (PM), dermatomyositis (DM), immune-mediated ...

Can We Differentiate Those Who Have the Self-limited Form of Statin Myopathy From Those Who Have the Immune-Mediated Variety? In our experience, most patients with autoimmune statin myopathy had ...

Geode Capital Management LLC boosted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 12.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,094 ...

Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has received an average rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One research analyst ...

Their findings highlight how a little-known member of the gut microbiome reshapes the lung immune environment to have both ... Study Shows Role of Cells' Own RNA in Antiviral Defense Dec.

Myositis, a complex autoimmune disorder affecting muscle tissue, encompasses various forms including dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis ...